Genmab — Maj 2021
-
"And the reason is that Genmab not only allowed access to the DuoBody technology platform by Janssen and to create panels of bispecifics. We also created -- physically created the eGFR arm and the CNET arm the panels with Janssen then used to build amivantamab from."
-
-
Nej, det har intet med voldgift og grumset at gøre. Det er bare JNJ der udlægger virkeligheden anderledes END virkeligheden
Men de er ikke uenige om royalties såvidt vides. Ikke endnu ihvertfald. Så man skal nok ikke puste til bjørnen før den skindet skindet og rejser sig og truer... -
Og tegn på dårligt samarbejde. Slet ikke. Bare et stort firma der på barnligste, kommercielle, vis fremhæver sig selv og underspiller andres vigtige fødder i scoringen. Lidt lissom' blærerøven i skolegården, der mente han alene lavede alle målene.. eller folk på de fleste direktørgange, som tildeler sig selv langt de største dele af overskudskagerne og skider på at HELE firmaet har været med!
-
Var det Bulder, der spurgte til suffixet i amivantamab: amivantamab-vmjw? Det er en tilfældig samling af bogstaver, som IKKE må have nogen mening og hvis funktion er at kunne skelne et biosimilært kopi-produkt fra det originale produkt. https://www.centerforbiosimilars.com/view/alphabet-soup-the-story-behind-biosimilar-nonproprietary-name-suffixes
-
Og her FDAs skriv "Nonproprietary Naming Guidance", på s.10 står om suffixet. https://www.fda.gov/files/drugs/published/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf
-
Og det MÅ IKKE: "•Be false or misleading, such as by making misrepresentations with respect to safety or efficacy•Include numerals and other symbols aside from the hyphen attaching the suffix to the core name•Include abbreviations commonly used in clinical practice in a manner that may lead the suffix to be misinterpreted as another element on the prescription or order•Contain or suggest any drug substance name or core name..
-
•Look similar to or be capable of being mistaken for the name of a currently marketed product (e.g., should not increase the risk of confusion or medical errors with the product and/or other products in the clinical setting)•Look similar to or otherwise connote the name of the license holder•Be too similar to any other FDA-designated nonproprietary name suffix"
-
Fra Janssens artikel: Dr. Knoblauch is hopeful that the drug will prove to be an effective treatment for other types of cancer, as well.
“There are several other types of tumors we can explore where one of the same genes that our bispecific binds to is overexpressed,” he says. “I’m looking forward to seeing if there is potential for this drug to help patients with other types of cancers, too.” https://www.jnj.com/innovation/journey-to-fda-approval-non-small-cell-lung-cancer-treatment
-
Enig Stroka. Jeg lægger artiklen op i debatten.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind